Literature DB >> 28024998

Development and validation of a cell-based fluorescent method for measuring antibody affinity.

Xin Yu1, Charles N Pegram2, Darell D Bigner3, Vidyalakshmi Chandramohan4.   

Abstract

Monoclonal antibodies have become essential tools for diagnostic and therapeutic purposes. Antibody affinity is one of the critical factors influencing the therapeutic success of tumor-targeting antibodies. Therefore, developing an accurate and reliable method for determining antibody affinity is crucial. In this study, we describe a fluorescent cell-based immunosorbent assay that can accurately measure antibody affinity (KD) in the nanomolar range. This method involves the addition of fluorescently labeled antibodies to antigen-positive and antigen-negative cell lines fixed on 96-well plates. The fluorescent signals from nonspecific binding to negative control cell lines is subtracted from the specific binding to the antigen-positive cell lines. The KD values obtained by this method were comparable with values obtained by the flow cytometry and radioactive (I125) scatchard assay. Our results demonstrate that this modified cell-based fluorescent method allows for a convenient and efficient identification of therapeutically relevant leads.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody affinity; Flow cytometry; Fluorescent cell-based assay; Scatchard

Mesh:

Substances:

Year:  2016        PMID: 28024998      PMCID: PMC5293658          DOI: 10.1016/j.jim.2016.12.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Rapid affinity measurement of protein-protein interactions in a microfluidic platform.

Authors:  Hossein Salimi-Moosavi; Palaniswami Rathanaswami; Surendran Rajendran; Mike Toupikov; John Hill
Journal:  Anal Biochem       Date:  2012-04-26       Impact factor: 3.365

2.  Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Authors:  Michael R Zalutsky; Abraham Boskovitz; Chien-Tsun Kuan; Charles N Pegram; Joanne Ayriss; Carol J Wikstrand; Anne F Buckley; Eric S Lipp; James E Herndon; Roger E McLendon; Darell D Bigner
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

3.  Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain.

Authors:  Yukinari Kato; Mika Kato Kaneko; Atsushi Kuno; Noboru Uchiyama; Koh Amano; Yasunori Chiba; Yasushi Hasegawa; Jun Hirabayashi; Hisashi Narimatsu; Kazuhiko Mishima; Motoki Osawa
Journal:  Biochem Biophys Res Commun       Date:  2006-09-07       Impact factor: 3.575

Review 4.  CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.

Authors:  Matthew A Price; Leah E Colvin Wanshura; Jianbo Yang; Jennifer Carlson; Bo Xiang; Guiyuan Li; Soldano Ferrone; Arkadiusz Z Dudek; Eva A Turley; James B McCarthy
Journal:  Pigment Cell Melanoma Res       Date:  2011-12       Impact factor: 4.693

5.  Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.

Authors:  Yukinari Kato; Ganesan Vaidyanathan; Mika Kato Kaneko; Kazuhiko Mishima; Nidhi Srivastava; Vidyalakshmi Chandramohan; Charles Pegram; Stephen T Keir; Chien-Tsun Kuan; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2010-10       Impact factor: 2.408

6.  Optimization of cellular ELISA for assay of surface antigens on human synoviocytes.

Authors:  D D Smith; C B Cohick; H B Lindsley
Journal:  Biotechniques       Date:  1997-05       Impact factor: 1.993

Review 7.  Advances in anticancer immunotoxin therapy.

Authors:  Christine Alewine; Raffit Hassan; Ira Pastan
Journal:  Oncologist       Date:  2015-01-05

8.  Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.

Authors:  C J Wikstrand; R E McLendon; A H Friedman; D D Bigner
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

Review 9.  Therapeutic application of monoclonal antibodies in cancer: advances and challenges.

Authors:  Helmout Modjtahedi; Sumaira Ali; Sharadah Essapen
Journal:  Br Med Bull       Date:  2012-10-31       Impact factor: 4.291

10.  Reactivity spectrum of 30 monoclonal antimelanoma antibodies to a panel of 28 melanoma and control cell lines.

Authors:  S Carrel; M Schreyer; A Schmidt-Kessen; J P Mach
Journal:  Hybridoma       Date:  1982
  10 in total
  1 in total

1.  Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.

Authors:  Tsung-Yi Lin; Jeong A Park; Alan Long; Hong-Fen Guo; Nai-Kong V Cheung
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 12.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.